Abstract
Members of the cell division cycle 25 (Cdc25) family of proteins are highly conserved dual specificity phosphatases, which play a fundamental role in transitions between cell cycle phases during normal cell division through the activation of CdK/cyclin complexes. Furthermore, they are important targets of checkpoints in cellular pathways in the response to DNA damage. Over the past few years, more information about the basic enzymology of the Cdc25 phosphatases has emerged, with the identification of three Cdc25 phosphatase isoforms (A, B, and C) in mammalians. In particular, the Cdc25 A and B phosphatases have oncogenic properties and are overexpressed singly in some types of cancers and together in others. Therefore, it is not surprising that the Cdc25s are interesting targets for the development of new anticancer therapeutic strategies. In this review, we examine the most important classes of reversible inhibitors that show specificity for the Cdc25 A and B phosphatases (both singly and together) and the recent advances in the design of new potent Cdc25 A and B inhibitors. Using computational methodologies, we also consider their plausible mechanisms of action.
Keywords: Cancer, dual-specificity phosphatases, Cdc25 inhibitors, cell cycle, antiproliferative agents, docking, molecular modelling
Current Medicinal Chemistry
Title: CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Volume: 16 Issue: 15
Author(s): Antonio Lavecchia, Carmen Di Giovanni and Ettore Novellino
Affiliation:
Keywords: Cancer, dual-specificity phosphatases, Cdc25 inhibitors, cell cycle, antiproliferative agents, docking, molecular modelling
Abstract: Members of the cell division cycle 25 (Cdc25) family of proteins are highly conserved dual specificity phosphatases, which play a fundamental role in transitions between cell cycle phases during normal cell division through the activation of CdK/cyclin complexes. Furthermore, they are important targets of checkpoints in cellular pathways in the response to DNA damage. Over the past few years, more information about the basic enzymology of the Cdc25 phosphatases has emerged, with the identification of three Cdc25 phosphatase isoforms (A, B, and C) in mammalians. In particular, the Cdc25 A and B phosphatases have oncogenic properties and are overexpressed singly in some types of cancers and together in others. Therefore, it is not surprising that the Cdc25s are interesting targets for the development of new anticancer therapeutic strategies. In this review, we examine the most important classes of reversible inhibitors that show specificity for the Cdc25 A and B phosphatases (both singly and together) and the recent advances in the design of new potent Cdc25 A and B inhibitors. Using computational methodologies, we also consider their plausible mechanisms of action.
Export Options
About this article
Cite this article as:
Lavecchia Antonio, Di Giovanni Carmen and Novellino Ettore, CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy, Current Medicinal Chemistry 2009; 16 (15) . https://dx.doi.org/10.2174/092986709788186084
DOI https://dx.doi.org/10.2174/092986709788186084 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Therapeutic Potential of Photochemically Active Metal Complexes based on Interaction with Enzymes
Current Topics in Medicinal Chemistry Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Effect of Treatment with Caspofungin on the Diagnosis of Fungal Infections by Gamma Scintigraphy
Current Radiopharmaceuticals Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Zebrafish as a Model for the Study of the Phase II Cytosolic Sulfotransferases
Current Drug Metabolism Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N
Mini-Reviews in Organic Chemistry